# US 2016/0354345 A1 · Method for preventing or treating diseases associated with a reduced density of interferon receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354345 A1
- Document ID: US20160354345A1
- Status: Published application
- Kind: A1
- Application number: 14/915,475
- Filed: 2014-09-01
- Published: 2016-12-08
- Earliest claimed: 2013-09-03
- Assignees: Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises”
- Applicants: Obschestvo S Ogranichennoi Otvetstvennostiyu ("Pharmenterprises")
- Inventors: Vladimir Evgenievich Nebolsin; Andrei Yurievich Egorov
- Web page: https://patentgrep.com/patent/US20160354345A1

## CPC

- A61K 31/417: Imidazole-alkylamines, e.g. histamine, phentolamine
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0031: {Rectum, anus}
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61K 9/485: {Inorganic compounds}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to medicine, in particular, to a method for preventing and/or treating a disease associated with a reduced density of interferon receptors, the method comprising administering an effective amount of glutaryl histamine or a pharmaceutically acceptable salt thereof. Said disease may be hepatitis B, herpes, papilloma virus infection, or multiple sclerosis. The invention also relates to a pharmaceutical composition for prevention and/or treatment of diseases associated with a reduced density of interferon receptors, wherein the composition comprises an effective amount of glutaryl histamine or a pharmaceutically acceptable salt thereof. The invention solves a problem of providing a novel agent effective for overcoming a resistance to interferon therapy in diseases selected from the group including hepatitis B, herpes, papilloma virus infection, or multiple sclerosis.

## Claims

### Claim 1

A method for preventing and/or treating a disease associated with a reduced density of interferon receptors, the method comprising administering an effective amount of glutaryl histamine or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein said disease is selected from the group consisting of hepatitis B, herpes, papilloma virus infection, and multiple sclerosis.

### Claim 3 (depends on 1)

The method of claim 1, wherein said prevention and/or treatment is performed by overcoming a resistance to therapy with interferon and/or by compensating a reduced expression level of interferon receptors in a long-term therapy with interferon.

### Claim 4 (depends on 1)

The method of claim 1, wherein said prevention comprises the prevention of tobacco smoking-induced immunosuppression associated with a degradation of interferon receptors in smokers, and said treatment is directed to overcome a resistance to interferon therapy in smokers.

### Claim 5 (depends on 1)

The method of claim 1, wherein the interferon receptors are interferon α (IFNα) and/or interferon β (IFNβ) receptors.

### Claim 6 (depends on 1)

The method of claim 1, wherein glutaryl histamine is administered in a solid form, and a duration of the administration is from 5 days to 12 months.

### Claim 7 (depends on 1)

The method of claim 1, wherein the dose of glutaryl histamine or a pharmaceutically acceptable salt thereof is from 0.1 to 100 mg/kg of human body weight per day.

### Claim 8 (depends on 1)

The method of claim 1, wherein a single dose of glutaryl histamine is 100 mg.

### Claim 9

A method for preventing and/or treating a disease selected from the group including hepatitis B, herpes, papilloma virus infection, and multiple sclerosis, the method comprising administering an effective amount of glutaryl histamine or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein glutaryl histamine is administered in a solid form, and a duration of the administration is from 5 days to 12 months.

### Claim 11 (depends on 9)

The method of claim 9, wherein the dose of glutaryl histamine or a pharmaceutically acceptable salt thereof is from 0.1 to 100 mg/kg of human body weight per day.

### Claim 12

A pharmaceutical composition for prevention and/or treatment of a disease associated with a reduced density of interferon receptors, the composition comprising an effective amount of glutaryl histamine or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein said disease is selected from the group including hepatitis B, herpes, papilloma virus infection, and multiple sclerosis.

### Claim 14 (depends on 12)

The pharmaceutical composition of claim 12, wherein said prevention and/or treatment is performed by overcoming a resistance to therapy with interferon and/or by compensating a reduced expression level of interferon receptors in a long-term therapy with interferon.

### Claim 15 (depends on 12)

The pharmaceutical composition of claim 12, wherein the interferon receptors are interferon α (IFNα) and/or interferon β (IFNβ) receptors.

### Claim 16 (depends on 12)

The pharmaceutical composition of claim 12, wherein the glutaryl histamine is in a solid dosage form.

### Claim 17 (depends on 12)

The pharmaceutical composition of claim 12, wherein the dose of glutaryl histamine or a pharmaceutically acceptable salt thereof is from 0.1 to 100 mg/kg of human body weight per day, preferably from 0.1 to 30 mg/kg, more preferably from 0.3 to 10 mg/kg when administered one or more times per day.

### Claim 18 (depends on 12)

A kit for prevention and/or treatment of a disease selected from the group including hepatitis B, herpes, papilloma virus infection, and multiple sclerosis, the kit comprising a composition of claim 12 and instructions for use thereof.
